Carol Giltner Gallagher, Director at Atara Biotherapeutics, Inc. (ATRA), sold 1,184 shares at $15.25 ($18K) on 2017-05-16, disclosed to the SEC on 2017-05-17.
Scheduled sale ($18k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ATRA | SELL | 2018-06-19 | $112K | — | Filing → |
| ATRA | SELL | 2018-05-16 | $13K | — | Filing → |
| ATRA | SELL | 2018-02-20 | $110K | — | Filing → |